Search our site 
Advanced Search
Home | Exam dates | Contact us | About us | Testimonials |

You are in Home >> Resources >> Clinical anaesthesia >> Coagulation


Created: 29/6/2004

Aprotinin acts as an inhibitor of human trypsin, plasmin and plasma and tissue kallikreins, by forming reversible enzyme-inhibitor complexes. Haemostasis is thus re-established by the inactivation of free plasmin. Antifibrinolytics have been shown to reduce bleeding in cardiac surgery following cardiopulmonary bypass.

Antifibrinolytics (e.g. Tranexamic acid) may be useful in bleeding involving mucosal surfaces, such as in dental surgery (particularly in patients with haemophilia and von Willebrand's disease), with excessive menstrual bleeding and with thrombocytopenia or platelet dysfunction. Antifibrinolytics are also sometimes given before certain operations associated with a high risk of serious bleeding. They may also have a platelet-sparing role in patients undergoing liver transplantation or cardiac surgery.

Risks associated with the use of antifibrinolytics

Antifibrinolytics can cause side-effects of nausea, vomiting and diarrhoea. Aprotinin may cause allergic reactions and localised thrombophlebitis. Antifibrinolytics are contraindicated in renal tract bleeding because of the risk of ureteric obstruction and colic.

SiteSection: Article
  Posting rules

     To view or add comments you must be a registered user and login  

Login Status  

You are not currently logged in.
UK/Ireland Registration
Overseas Registration

  Forgot your password?

All rights reserved © 2021. Designed by AnaesthesiaUK.

{Site map} {Site disclaimer} {Privacy Policy} {Terms and conditions}

 Like us on Facebook